O Shaughnessy Asset Management LLC Buys 56,202 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

O Shaughnessy Asset Management LLC grew its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 99.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 112,571 shares of the biopharmaceutical company’s stock after acquiring an additional 56,202 shares during the quarter. O Shaughnessy Asset Management LLC owned about 0.23% of Puma Biotechnology worth $343,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Gateway Wealth Partners LLC bought a new stake in Puma Biotechnology during the 4th quarter valued at about $31,000. C2C Wealth Management LLC purchased a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $37,000. Franklin Resources Inc. bought a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $41,000. SG Americas Securities LLC raised its holdings in Puma Biotechnology by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 11,252 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Puma Biotechnology in the 3rd quarter valued at approximately $68,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Analyst Upgrades and Downgrades

PBYI has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 8th.

Puma Biotechnology Stock Up 2.9 %

Shares of Puma Biotechnology stock opened at $2.82 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a twelve month low of $2.23 and a twelve month high of $5.52. The company has a market cap of $139.90 million, a price-to-earnings ratio of 5.88 and a beta of 1.34. The company’s 50 day moving average is $3.09 and its 200 day moving average is $3.00.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.29. The firm had revenue of $59.10 million for the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. Research analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.